The role of intravenous iron in anemia management and transfusion avoidance. (otvara novi prozor)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Izvor‎: Transfusion 2008;48(5):988-1000.

Indeks‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (otvara novi prozor)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (otvara novi prozor)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Izvor‎: BJU Int 2011;108(10):1582-7.

Indeks‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (otvara novi prozor)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (otvara novi prozor)

Lepor H, Lipkin M, Slova D.

Izvor‎: Urology 2010;75(6):1424-8.

Indeks‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (otvara novi prozor)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (otvara novi prozor)

Nieder AM, Rosenblum N, Lepor H.

Izvor‎: Urology 2001;57(4):737-41.

Indeks‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (otvara novi prozor)